Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
2024-03-08 14:02:46 ET More on Merck Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Dividend Growth Stock, But Not At This Price Merck: A High-Conviction Investment For Long-Term Growth Gilead, Merck once we...
2024-03-08 12:11:45 ET More on IDEAYA, Immunocore, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Ideaya Biosciences: A Strong Bet In Targeted Oncology Immunocore Holdings: Vulnerable To Profit Taking After Big Rally Immunocore to work w...
2024-03-08 05:10:00 ET Summary BeiGene's revenue surged 73.7% to $2.46 billion last year. But for all the success with its flagship product, the drug maker was not able to power all the way into the black. Undeterred by the continuing losses, investors welcomed the bumper sale...
2024-03-05 14:33:12 ET More on Sandoz Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal Historical earnings data for Sandoz Group AG Finan...
2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
2024-02-14 21:40:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...
2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 09:33:11 ET Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using loru...
2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...